Remedent, Inc. (REMI)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 91.88 Thousand USD | -0.98% |
| 2023 | 92.79 Thousand USD | -1.8% |
| 2022 | 94.49 Thousand USD | -7.67% |
| 2021 | 102.34 Thousand USD | 12.66% |
| 2020 | 90.84 Thousand USD | -18.13% |
| 2019 | 110.96 Thousand USD | -9.87% |
| 2018 | 123.11 Thousand USD | 11.51% |
| 2017 | 110.4 Thousand USD | -73.12% |
| 2016 | 410.74 Thousand USD | -0.79% |
| 2015 | 414.03 Thousand USD | -30.91% |
| 2014 | 599.25 Thousand USD | -39.58% |
| 2013 | 991.8 Thousand USD | -7.98% |
| 2012 | 1.07 Million USD | -50.2% |
| 2011 | 2.16 Million USD | 0.11% |
| 2010 | 2.16 Million USD | 11.55% |
| 2009 | 1.93 Million USD | 42.42% |
| 2008 | 1.36 Million USD | 20.1% |
| 2007 | 1.13 Million USD | -22.96% |
| 2006 | 1.47 Million USD | 163.38% |
| 2005 | 558.33 Thousand USD | 29.45% |
| 2004 | 431.31 Thousand USD | 269.18% |
| 2003 | 116.83 Thousand USD | -99.88% |
| 2002 | 97.54 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q4 | 91.88 Thousand USD | 0.44% |
| 2024 FY | 91.88 Thousand USD | -0.98% |
| 2024 Q3 | 91.47 Thousand USD | 2.83% |
| 2024 Q2 | 88.96 Thousand USD | -2.91% |
| 2024 Q1 | 91.62 Thousand USD | -1.26% |
| 2023 Q4 | 92.79 Thousand USD | 4.94% |
| 2023 Q1 | 89.85 Thousand USD | 0.0% |
| 2023 FY | 92.79 Thousand USD | -1.8% |
| 2023 Q2 | 85.01 Thousand USD | -5.38% |
| 2023 Q3 | 88.42 Thousand USD | 4.01% |
| 2022 FY | 94.49 Thousand USD | -7.67% |
| 2021 Q3 | 107.58 Thousand USD | -4.86% |
| 2021 FY | 102.34 Thousand USD | 12.66% |
| 2021 Q2 | 113.07 Thousand USD | 13.37% |
| 2021 Q1 | 99.74 Thousand USD | 9.8% |
| 2020 Q2 | 128.91 Thousand USD | 16.28% |
| 2020 Q4 | 90.84 Thousand USD | -23.75% |
| 2020 FY | 90.84 Thousand USD | -18.13% |
| 2020 Q3 | 119.14 Thousand USD | -7.58% |
| 2020 Q1 | 110.86 Thousand USD | -0.09% |
| 2019 FY | 110.96 Thousand USD | -9.87% |
| 2019 Q1 | 114.73 Thousand USD | -6.81% |
| 2019 Q2 | 111.88 Thousand USD | -2.48% |
| 2019 Q3 | 110.85 Thousand USD | -0.93% |
| 2019 Q4 | 110.96 Thousand USD | 0.1% |
| 2018 Q4 | 123.11 Thousand USD | -1.58% |
| 2018 Q3 | 125.09 Thousand USD | 2.52% |
| 2018 FY | 123.11 Thousand USD | 11.51% |
| 2018 Q2 | 122.01 Thousand USD | 4.85% |
| 2018 Q1 | 116.36 Thousand USD | 5.4% |
| 2017 Q3 | 361.74 Thousand USD | -7.24% |
| 2017 Q1 | 401.08 Thousand USD | -2.35% |
| 2017 Q2 | 389.99 Thousand USD | -2.76% |
| 2017 FY | 110.4 Thousand USD | -73.12% |
| 2017 Q4 | 110.4 Thousand USD | -69.48% |
| 2016 Q3 | 401.86 Thousand USD | 3.89% |
| 2016 Q1 | 397.01 Thousand USD | -4.11% |
| 2016 Q2 | 386.82 Thousand USD | -2.57% |
| 2016 Q4 | 410.74 Thousand USD | 2.21% |
| 2016 FY | 410.74 Thousand USD | -0.79% |
| 2015 Q3 | 503.31 Thousand USD | -6.7% |
| 2015 FY | 414.03 Thousand USD | -30.91% |
| 2015 Q4 | 414.03 Thousand USD | -17.74% |
| 2015 Q1 | 592.7 Thousand USD | -1.09% |
| 2015 Q2 | 539.46 Thousand USD | -8.98% |
| 2014 Q1 | 959.37 Thousand USD | -3.27% |
| 2014 Q2 | 984.67 Thousand USD | 2.64% |
| 2014 Q3 | 974.51 Thousand USD | -1.03% |
| 2014 Q4 | 599.25 Thousand USD | -38.51% |
| 2014 FY | 599.25 Thousand USD | -39.58% |
| 2013 Q3 | 1.06 Million USD | -1.23% |
| 2013 Q2 | 1.07 Million USD | 3.21% |
| 2013 Q1 | 1.04 Million USD | -3.45% |
| 2013 FY | 991.8 Thousand USD | -7.98% |
| 2013 Q4 | 991.8 Thousand USD | -6.51% |
| 2012 FY | 1.07 Million USD | -50.2% |
| 2012 Q2 | 1.99 Million USD | -12.92% |
| 2012 Q3 | 1.08 Million USD | -45.56% |
| 2012 Q4 | 1.07 Million USD | -0.93% |
| 2012 Q1 | 2.29 Million USD | 6.04% |
| 2011 Q2 | 2.14 Million USD | 15.7% |
| 2011 FY | 2.16 Million USD | 0.11% |
| 2011 Q4 | 2.16 Million USD | 6.02% |
| 2011 Q3 | 2.04 Million USD | -4.69% |
| 2011 Q1 | 1.85 Million USD | -14.38% |
| 2010 FY | 2.16 Million USD | 11.55% |
| 2010 Q4 | 2.16 Million USD | -10.53% |
| 2010 Q1 | 2.05 Million USD | 6.1% |
| 2010 Q2 | 2.08 Million USD | 1.24% |
| 2010 Q3 | 2.41 Million USD | 16.06% |
| 2009 Q3 | 1.93 Million USD | 6.68% |
| 2009 FY | 1.93 Million USD | 42.42% |
| 2009 Q4 | 1.93 Million USD | 0.07% |
| 2009 Q2 | 1.81 Million USD | 25.13% |
| 2009 Q1 | 1.45 Million USD | 6.61% |
| 2008 Q3 | 1.12 Million USD | 10.08% |
| 2008 Q4 | 1.36 Million USD | 20.53% |
| 2008 Q2 | 1.02 Million USD | 10.55% |
| 2008 Q1 | 927.68 Thousand USD | -18.12% |
| 2008 FY | 1.36 Million USD | 20.1% |
| 2007 FY | 1.13 Million USD | -22.96% |
| 2007 Q4 | 1.13 Million USD | -6.5% |
| 2007 Q2 | 1.38 Million USD | 1.31% |
| 2007 Q3 | 1.21 Million USD | -12.55% |
| 2007 Q1 | 1.36 Million USD | -7.0% |
| 2006 Q3 | 1.27 Million USD | 66.87% |
| 2006 Q4 | 1.47 Million USD | 15.33% |
| 2006 Q2 | 764.14 Thousand USD | 19.28% |
| 2006 Q1 | 640.63 Thousand USD | 14.74% |
| 2006 FY | 1.47 Million USD | 163.38% |
| 2005 Q3 | 419.52 Thousand USD | 15.28% |
| 2005 Q2 | 363.91 Thousand USD | 9.5% |
| 2005 FY | 558.33 Thousand USD | 29.45% |
| 2005 Q1 | 332.34 Thousand USD | -22.95% |
| 2005 Q4 | 558.33 Thousand USD | 33.09% |
| 2004 Q3 | 390.72 Thousand USD | 54.66% |
| 2004 Q1 | 183.76 Thousand USD | 57.29% |
| 2004 FY | 431.31 Thousand USD | 269.18% |
| 2004 Q4 | 431.31 Thousand USD | 10.39% |
| 2004 Q2 | 252.62 Thousand USD | 37.47% |
| 2003 Q1 | 82.98 Thousand USD | -14.93% |
| 2003 Q2 | 112.12 Thousand USD | 35.12% |
| 2003 FY | 116.83 Thousand USD | -99.88% |
| 2003 Q4 | 116.83 Thousand USD | 24.91% |
| 2003 Q3 | 93.53 Thousand USD | -16.58% |
| 2002 Q3 | 148.81 Thousand USD | -32.65% |
| 2002 Q2 | 220.93 Thousand USD | 184.09% |
| 2002 Q1 | 77.77 Thousand USD | -6.19% |
| 2002 FY | 97.54 Million USD | 0.0% |
| 2002 Q4 | 97.54 Thousand USD | -34.45% |
| 2001 Q3 | 115.49 Thousand USD | 2.57% |
| 2001 Q2 | 112.59 Thousand USD | 2.69% |
| 2001 Q4 | 82.9 Thousand USD | -28.22% |
| 2001 Q1 | 109.64 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| American Medical Technologies Inc. | 133.82 Thousand USD | 31.344% |
| Ansell Limited | 457.04 Million USD | 99.98% |
| Ansell Limited | 457.9 Million USD | 99.98% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 43.33 Million USD | 99.788% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 27.89 Thousand USD | -229.444% |
| Psykey, Inc. | 49.94 Thousand USD | -83.985% |
| ConvaTec Group Plc | 395.54 Million USD | 99.977% |
| ConvaTec Group Plc | 396.1 Million USD | 99.977% |
| Encision Inc. | 1.4 Million USD | 93.448% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | -9294.00 USD | 1088.616% |
| LifePoint, Inc. | 2.3 Million USD | 96.021% |
| Medite Cancer Diagnostics, Inc. | 2.4 Million USD | 96.176% |
| Paradigm Medical Industries, Inc. | 441 Thousand USD | 79.165% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Reflect Scientific, Inc. | 972.29 Thousand USD | 90.55% |
| SmileDirectClub, Inc. | 49.87 Million USD | 99.816% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 351.74 Million USD | 99.974% |
| SheerVision, Inc. | 339.66 Thousand USD | 72.949% |
| United Health Products, Inc. | 33.59 Thousand USD | -173.475% |
| Vasamed, Inc. | 449.02 Thousand USD | 79.538% |
| Wearable Health Solutions, Inc. | 8555.00 USD | -974.015% |
| Yubo International Biotech Limited | 322.17 Thousand USD | 71.481% |